View ongoing clinical trial, registries, repositories, and cohort opportunities related to rheumatology and rheumatic diseases.
- Clinical Trials
- Registries
- Repositories
- Cohorts
Tocilizumab for Refractory Polymyositis and Dermatomyositis
Title
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
WIRB PRO Number
14010105
Clinical Trial Summary
Although tocilizumab is FDA-approved for use in rheumatoid arthritis, it is considered experimental when used for myositis.
Basic inclusion criteria are: (1) medical diagnosis of polymyositis (PM) or dermatomyositis (DM); (2) symptoms of active disease, such as weakness of the large muscles closest to the trunk of the body, and/or abnormal muscle enzymes, and/or rash of DM; (3) have experienced little or no improvement of symptoms in response to taking steroids (prednisone) or other immunosuppressive (IS) medications, or could not tolerate other IS medications.
Purpose
To examine the effectiveness of tocilizumab in adult myositis patients.
Learn More
cla24@pitt.edu
412-648-9989
clinicaltrials.gov - NCT02043548
Belimumab as a Therapy for Idiopathic Inflammatory Myositis
Title
Belimumab in Myositis
IRB Number
14-621
Clinical Trial Summary
Idiopathic inflammatory myositis (IIM) is characterized by chronic inflammation of muscle tissue and other organ systems. Current treatment strategies have limited efficacy and carry a significant toxicity burden. A small number of studies have demonstrated the role of the BLyS/BAFF pathway in IIM. Targeting the BLyS/BAFF pathway may offer a new and safe approach to maintenance therapy in IIM.
Purpose
The goal of the trial is to evaluate the efficacy and safety of belimumab as a maintenance therapy in adults with refractory Idiopathic Inflammatory Myositis (IIM) as compared with standard of care. This is a multicenter double-blind, placebo-controlled trial.
Learn More
pnandkumar@nshs.edu
Phone: 516-708-2556
clinicaltrials.gov – ID # NCT02347891
Belimumab (BENLYSTA) Pregnancy Registry
Title
Belimumab (BENLYSTA) Pregnancy Registry
WIRB PRO Number
20111738
Clinical Trial Summary
Pregnant women who have been given belimumab within the four months prior to and/or during pregnancy are eligible to take part in the Registry.
Purpose
The purpose of the Registry is to study the health of eligible pregnant women until they give birth, and to study the health of their babies until they are 12 months old.
Learn More
belimumab.pregnancy@ppdi.com
877-681-6296
bprgsk.com
pregnancyregistry.gsk.com
Please note that while IRB approval is verified by ACR staff, these opportunities are not endorsed or supported by the ACR.